2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

N Sayegh,Y Jung Jo,G Gebrael,N Tripathi,B Chigarira,A Srivastava,B Nordblad,E Dal,C Hage Chehade,B.L Maughan,S Gupta,N Agarwal,U Swami

doi:10.1016/j.annonc.2023.09.1029

2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

N Sayegh, Y Jung Jo + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.1029

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: Huntsman Cancer Institute

#Enfortumab Vedotin #Metastatic Urothelial Carcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

Full Text